AC Immune S.A. (ACIU)

Nov 14, 2024, 10:32 AM EST - 4 months ago

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

Jul 31, 2024, 8:30 AM EDT - 7 months ago

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

Jul 26, 2024, 3:10 PM EDT - 8 months ago

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 25, 2024, 7:00 AM EDT - 8 months ago

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease

May 28, 2024, 7:00 AM EDT - 10 months ago

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

May 13, 2024, 8:47 AM EDT - 10 months ago

Alzheimer's vaccine licensing deal boosts AC Immune

May 13, 2024, 6:05 AM EDT - 10 months ago

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 13, 2024, 6:00 AM EDT - 10 months ago

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

TAK

Mar 14, 2024, 7:00 AM EDT - 1 year ago

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Feb 22, 2024, 7:00 AM EST - 1 year ago

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

Jan 22, 2024, 7:00 AM EST - 1 year ago

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

Jan 3, 2024, 8:10 AM EST - 1 year ago

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

Dec 18, 2023, 6:25 PM EST - 1 year ago

AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts

Dec 15, 2023, 7:56 AM EST - 1 year ago

AC Immune Announces Pricing of Underwritten Offering of Common Shares

Dec 15, 2023, 7:22 AM EST - 1 year ago

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

Dec 1, 2023, 7:00 AM EST - 1 year ago

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

Nov 7, 2023, 7:00 AM EST - 1 year ago

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

Nov 3, 2023, 7:00 AM EDT - 1 year ago

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Nov 2, 2023, 7:00 AM EDT - 1 year ago

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

Oct 27, 2023, 7:00 AM EDT - 1 year ago

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

Oct 17, 2023, 7:00 AM EDT - 1 year ago

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

Oct 5, 2023, 7:00 AM EDT - 1 year ago

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

Sep 5, 2023, 7:00 AM EDT - 1 year ago

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

Aug 4, 2023, 7:00 AM EDT - 1 year ago

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Jul 28, 2023, 7:00 AM EDT - 1 year ago

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

Jul 26, 2023, 7:00 AM EDT - 1 year ago

AC Immune SA Appoints New Chief Medical Officer

Jul 3, 2023, 7:00 AM EDT - 1 year ago

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

Jun 27, 2023, 7:52 AM EDT - 1 year ago

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

Jun 27, 2023, 7:00 AM EDT - 1 year ago

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

Jun 23, 2023, 4:30 PM EDT - 1 year ago

AC Immune Holds Annual General Meeting of Shareholders

Apr 28, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Apr 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

Mar 20, 2023, 8:00 AM EDT - 2 years ago

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

Mar 18, 2023, 9:00 AM EDT - 2 years ago

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

Mar 16, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 8, 2023, 7:00 AM EST - 2 years ago

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

Feb 7, 2023, 7:00 AM EST - 2 years ago

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

Feb 2, 2023, 8:15 AM EST - 2 years ago

AC Immune to Present at the SVB Securities Global Biopharma Conference

Jan 26, 2023, 7:00 AM EST - 2 years ago

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Jan 18, 2023, 7:00 AM EST - 2 years ago

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

Dec 27, 2022, 1:02 PM EST - 2 years ago

Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket

Nov 30, 2022, 7:00 AM EST - 2 years ago

AC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Nov 23, 2022, 7:30 AM EST - 2 years ago

AC Immune to Present Progress of Alzheimer's Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

Nov 8, 2022, 7:58 AM EST - 2 years ago

AC Immune to Present at the Jefferies London Healthcare Conference

Oct 28, 2022, 8:00 AM EDT - 2 years ago

AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Sep 26, 2022, 7:30 AM EDT - 2 years ago

AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer's Disease

Aug 24, 2022, 4:05 PM EDT - 2 years ago

AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer's and Parkinson's Diseases

Aug 2, 2022, 11:00 AM EDT - 2 years ago

Detailed Data From the Phase II Crenezumab Alzheimer's Prevention Initiative Study in Autosomal Dominant Alzheimer's Disease Presented at AAIC

Jul 28, 2022, 7:30 AM EDT - 2 years ago

AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 22, 2022, 7:30 AM EDT - 2 years ago

AC Immune Announces Upcoming Presentations at the Alzheimer's Association International Conference